Crossmark

Disproportionality analysis highlights paradoxical psoriasis as a clinically significant class effect of tumor necrosis-α inhibitors in pediatric populations

Crossref DOI link: https://doi.org/10.1038/s41390-025-04518-8

Published Online: 2025-10-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lynch, Fiona https://orcid.org/0000-0003-0026-9117
Irvine, Alan D.
License Information

Text and Data Mining valid from 2025-10-20

Version of Record valid from 2025-10-20
More Information

Article History

Received: 5 August 2025

Accepted: 14 August 2025

First Online: 20 October 2025

Competing interests

: The authors report the following conflicts of interest: F.L.—none. A.I.—AbbVie, Arena Pharmaceuticals, BenevolentAI, Chugai Pharmaceutical, Dermavant, Eli Lilly, Genentech, LEO Pharma, Menlo Therapeutics, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Sitryx, UCB—consultant; AbbVie, Eli Lilly, LEO Pharma, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi – speaker; AbbVie, Inflazome, Novartis, Sanofi-Regeneron Pharmaceuticals Inc.—investigator; Sanofi-Regeneron Pharmaceuticals Inc.—patent holder.

Document is current

Any future updates will be listed below